Subtype
Nasopharyngeal Neoplasm
CI-CAN-00003401Explore in graph →
Non-malignant267 active trials1 approved drugs
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003401Explore in graph →
Clinical trials
825 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04605562 | Umbrella Biomarker-Guided Therapy in NPC | not yet recruiting | Phase 2 | 206 | Sun Yat-sen UniversityOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02512315 | A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma | unknown | Phase 3 | 192 | Sun Yat-sen UniversityOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT05020067 |
| Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy |
| completed |
| Phase 2 |
| 90 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Aug 25, 2021 |
| clinicaltrials |
| NCT05020925 | SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT03668730 | Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 | 215 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04992988 | Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial | unknown | Phase 2 | 40 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT01094405 | Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy | completed | Phase 2 | 25 | Chinese University of Hong KongOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT04376866 | Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 204 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04955886 | Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 14 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03904225 | Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis | unknown | Phase 2 | 220 | Zhejiang Cancer HospitalOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT00430378 | Acupuncture for Prevention of Radiation-Induced Xerostomia | completed | N/A | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT04917770 | The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 28 | West China HospitalOTHER | 0 | Jun 8, 2021 | clinicaltrials |
| NCT03353467 | Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients | recruiting | N/A | 228 | Sun Yat-sen UniversityOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT04890522 | An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC | not yet recruiting | Phase 2 / Phase 3 | 622 | Sun Yat-sen UniversityOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy | withdrawn | Phase 2 | 0 | The University of Hong KongOTHER | 0 | May 3, 2021 | clinicaltrials |
| NCT03379610 | A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy | completed | — | 426 | The University of Hong KongOTHER | 0 | Apr 30, 2021 | clinicaltrials |
| NCT04745741 | Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC | unknown | — | 200 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 29, 2021 | clinicaltrials |
| NCT00896181 | Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 26 | Stanford UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04810936 | Early Nutritional Intervention in NPC Patients Undergoing Concurrent Chemoradiotherapy | unknown | N/A | 272 | Guangdong Provincial People's HospitalOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT04778956 | Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 218 | Sun Yat-sen UniversityOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04769076 | The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 25, 2021 | clinicaltrials |
| NCT04215510 | Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT | not yet recruiting | Phase 3 | 286 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04766359 | Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma | unknown | Phase 3 | 364 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 23, 2021 | clinicaltrials |
| NCT04764149 | Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma | unknown | — | 801 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03668366 | S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 133 | Fudan UniversityOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT02636231 | Endostar for Locally Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01817023 | The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT | unknown | Phase 3 | 590 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03908372 | Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03915132 | Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 | 47 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT04724590 | OPHTHALMOLOGIC EVALUATION OF RADIATION-RELATED OPTIC NEUROPATHY FOLLOWING IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY (IMRT) FOR NASOPHARYNGEAL CARCİNOMA(ORONIN) | unknown | N/A | 15 | Istanbul University - CerrahpasaOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT03601390 | Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPC | completed | — | 387 | Sun Yat-sen UniversityOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT00342147 | Family Study of Head and Neck Cancers in Taiwan | completed | — | 3,795 | National Cancer Institute (NCI)NIH | 1 | Dec 11, 2020 | clinicaltrials |
| NCT02586532 | Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China | completed | — | 828 | National Cancer Institute (NCI)NIH | 1 | Dec 11, 2020 | clinicaltrials |
| NCT04627961 | A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 33 | National University Hospital, SingaporeOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | withdrawn | Phase 2 | 0 | Alain AlgaziOTHER | 0 | Oct 26, 2020 | clinicaltrials |
| NCT03656250 | Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI | completed | — | 17 | NYU Langone HealthOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03025854 | Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma | unknown | — | 600 | Sun Yat-sen UniversityOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT04387266 | To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC | completed | — | 471 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 9, 2020 | clinicaltrials |
| NCT04448522 | Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma | recruiting | Phase 3 | 508 | Sun Yat-sen UniversityOTHER | 2 | Sep 28, 2020 | clinicaltrials |
| NCT04453813 | Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 226 | Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04453826 | Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 388 | Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT03048305 | Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue | unknown | — | 200 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2020 | clinicaltrials |
| NCT03129412 | Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions | unknown | Phase 2 | 64 | Zhejiang Cancer HospitalOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT04553510 | Treatment of Bevacizumab Followed by Steroid in RN | unknown | Phase 2 | 86 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT04547088 | Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04548271 | Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04538547 | Randomized Trial to Evaluate Accelerated Radiotherapy in Locally Advanced Carcinoma of Nasopharynx(EARN) | unknown | N/A | 120 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03989297 | PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma | completed | — | 104 | Kiang Wu HospitalOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT04534855 | A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 0 | Sep 1, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Sep 5, 2021source: clinicaltrials